# A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)

> **NCT04994288** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.** · enrollment: 547 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **BIOLOGICAL:** Supaglutide injection
- **OTHER:** placebo injection

## Key facts

- **NCT ID:** NCT04994288
- **Lead sponsor:** Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-03
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-08-16
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04994288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04994288, "A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04994288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*